| Name | N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide |
|---|---|
| Synonyms |
Glisoxepida [INN-Spanish]
Glisepin Glisoxepida Glisoxepid Glisoxepide 5-methyl-isoxazole-3-carboxylic acid 4-(azepan-1-ylcarbamoyl-sulfamoyl)-phenethylamide Glisoxepida [Spanish] N-{2-[4-({[(azepan-1-ylamino)carbonyl]amino}sulfonyl)phenyl]ethyl}-5-methylisoxazole-3-carboxamide Glisoxepidum Glisoxepidum [INN-Latin] N-{2-[4-({[(azepan-1-yIamino)carbonyI]amino}suIfonyl)phenyI]ethyI}-5-methylisoxazole-3-carboxamide Glisoxepide (INN) Pro-Diaban |
| Description | Glisoxepide, a sulphonamide derivative, is an orally available nonselective K(ATP) channel blocker, with antihyperglycemic activity and cardiovascular regulation effect[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
K(ATP) channel[1] |
| In Vitro | Glisoxepide inhibits the uptake of bile acids into isolated rat hepatocytes[3]. Glisoxepide noncompetitively inhibits the cholate uptake with a Ki of 200 μM[3]. |
| References |
| Density | 1.37g/cm3 |
|---|---|
| Molecular Formula | C20H27N5O5S |
| Molecular Weight | 449.52400 |
| Exact Mass | 449.17300 |
| PSA | 142.02000 |
| LogP | 3.92580 |
| Index of Refraction | 1.617 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
|
~%
25046-79-1 |
| Literature: Arzneimittel-Forschung, , vol. 24, # 0 p. 363 - 374 |
|
~%
25046-79-1 |
| Literature: Arzneimittel-Forschung, , vol. 24, # 0 p. 363 - 374 |
|
~%
25046-79-1 |
| Literature: Arzneimittel-Forschung, , vol. 24, # 0 p. 363 - 374 |
|
~%
25046-79-1 |
| Literature: Arzneimittel-Forschung, , vol. 24, # 0 p. 363 - 374 |
| Precursor 5 | |
|---|---|
| DownStream 0 | |